Dislog Group expands in pharma with Farmalac acquisition

Dislog Group has announced a strategic partnership with Farmalac to acquire the entire capital of Farmalac in exchange for a share swap with Dislog Group. This move is part of Dislog's external growth strategy (M&A) and will strengthen its position in the pharmaceutical industry, particularly in the distribution of packaging materials and raw materials.

Founded in 1997 by the late Luigi Ghizlanzoni, Farmalac is a leading player in the healthcare sector. Since 2022, it has expanded its business to include the marketing of reagents and consumables for laboratories, further solidifying its role as a key supplier.

In 2024, Farmalac achieved a turnover of 251 million dirhams, with the majority coming from the pharmaceutical sector. Farmalac will be integrated into Dislog Group’s health division, with Mounir Serifi appointed CEO. No additional governance changes are planned.

Moncef Belkhayat, President of Dislog Group, expressed excitement over the acquisition, noting that it strengthens the group's health division and expands its offerings to better meet market demands.

Founded in 2005, Dislog Group is a Moroccan industrial group operating in the hygiene, food, and health sectors, with a strong presence in both Morocco and Europe.

Dislog Group was advised by Maître Rachid Hilmi, while Farmalac was represented by the law firm DLA Piper.